IP Library Granted Patent US 11,918,547
Granted Patent B2
US 11,918,547 · App. 17/675,664 · Granted Mar 5, 2024

Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Inventors: Mei Feng Hong (Seattle, WA); Qi Jia (Olympia, WA); Lidia Alfaro Brownell (Tacoma, WA)
A61K31/05A61K8/347A61K31/60A61Q19/02A61K2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,918,547
App. No.
17/675,664
Granted
Mar 5, 2024
Kind
B2
Abstract

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

Claims (8)

1. A method for neutralizing reactive oxygen species and protecting melanocytes from oxidative stress under inflammation conditions in a deep layer of skin, the method comprising administering to a mammal an effective amount of a composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one preservative, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.

2. The method of claim 1 , wherein the preservative comprises phenoxyethanol, chlorphenesin, or a combination thereof.

3. The method of claim 1 , wherein the at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof comprises α-hydroxyacids, salicylic acid, p-linoleic acid, retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin, erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc, estrogen and its derivatives, chlorphenesin, anti-androgens, sulfur, corticosteroids, cortisone, tazarotene, curcumin extract, acacia extract, scutellaria extract, green tea extract, grape seed extract, or a combination thereof.

4. A composition for neutralizing reactive oxygen species and protecting melanocytes from oxidative stress under inflammation conditions in a deep layer of skin comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one preservative, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.

5. The composition of claim 4 , wherein the preservative comprises phenoxyethanol, chlorphenesin, or a combination thereof.

6. The composition of claim 4 , wherein at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof comprises α-hydroxyacids, salicylic acid, linoleic acid, retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin, erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc, estrogen and its derivatives, chlorphenesin, anti-androgens, sulfur, corticosteroids, cortisone, tazarotene, curcumin extract, acacia extract, scutellaria extract, green tea extract, grape seed extract, or a combination thereof.

7. A method for neutralizing reactive oxygen species and protecting melanocytes from oxidative stress under inflammation conditions in a deep layer of skin, the method comprising administering to a mammal an effective amount of a composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.

8. A composition for neutralizing reactive oxygen species and protecting melanocytes from oxidative stress under inflammation conditions in a deep layer of skin comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.

Continuity (7)
Continuation 16876333 · May 18, 2020
Continuation In Part 16594759 · Oct 7, 2019
Continuation 15628449 · Jun 20, 2017
Continuation 13365172 · Feb 2, 2012
Continuation In Part PCTUS2011026594 · Mar 1, 2011
Provisional Application 61438890 · Feb 2, 2011
Related Publication 20220401379A1 · Dec 22, 2022